Phase 2 Chronic Kidney Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 18 and 60 years of age.
- People who have been diagnosed with end-stage kidney disease and are currently receiving regular dialysis.
- People whose immune system has developed a very high level of antibodies that make it extremely difficult to find a compatible kidney donor (specifically, a calculated Panel Reactive Antibody level of 95% or higher).
- People who are currently on the active waiting list for a deceased-donor kidney transplant.
- People whose bone marrow, liver, heart, and lungs are healthy enough to safely go through the treatment process involved in this trial (confirm with trial site).
- People who are able to understand what the study involves and are willing to sign a written consent form.
Who may not be able to join:
- People who cannot safely receive any of the specific medications used to prepare the body for the procedure in this trial (rituximab, cyclophosphamide, or rATG).
- People who have an active, uncontrolled infection, or certain ongoing infections such as HIV, active Hepatitis B or C, or active tuberculosis.
- People who have significant heart problems, such as a heart that is not pumping well enough, or severe lung disease.
- People who have had a cancer diagnosis within the past 5 years, with the exception of certain treated skin cancers that did not spread (confirm with trial site for specific details).
- People who have previously undergone any type of stem cell transplant.
- People who are currently pregnant or breastfeeding.
- People whose mental health, physical health, or location makes it difficult, in the treating doctor's assessment, to follow the trial requirements and attend long-term follow-up appointments.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Oriol Bestard, Hospital Vall d'Hebron
Phone: 34932607400
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Calculated Panel Reactive Antibody (cPRA) Levels; Incidence of Treatment-Emergent Adverse Events (Safety Profile)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.